Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Guess That Market | Main | Fresh Air, Or What Passes For It »

September 10, 2007

Have We Got A Deal For You!

Email This Entry

Posted by Derek

After mentioning orphan drugs yesterday, I note that Kyle at The Chemblog has remarked on Genzyme's pricing for Cerezyme. It is indeed spectacularly expensive, which is a matter over which Genzyme and the various insurance companies involved have had, I'm sure, many a spirited discussion.

As it happens, Genzyme was in the news today (front page of the Boston Globe), with the kind of story that no one at a company likes to see. It's all about a shareholder lawsuit, just recently settled, which maintains that Genzyme bought back shares of a tracking stock (for their biosurgery division) at a deliberately depressed price. The existing shareholders were deeply unhappy about the deal they were offered, but basically had to roll over and take it (until they went to court, anyway).

There are some lurid figures in the story. Genzyme bought the shares back at $1.77. Meanwhile, a price of $75 per share had been mentioned just days before, which sounds like piracy, for sure. But when you read the story closely, you find that this figure was mooted by the head of the biosurgery division, who actually quoted a range of 12.75 to 75. Three things come to mind: (1) those sure are some error bars, (2) any estimate with that kind of spread to it is a worthless one, and (3) this figure is from a person who had an incentive to make his division (and his leadership of it) look as good as possible.

At any rate, the buyback cost $72 million at 1.77, and adding in the settlement makes the actual price per share about 3.34. If there were a remote chance that that 12.75 price could have been enforced in court, the lawyers involved wouldn't have gone for it, I think. (Much less that 75-dollar figure).

That said, it was in Genzyme's interest to buy back the shares at the lowest possible price. If I'd been a shareholder of the tracking stock, I wouldn't have been happy - after all, 1.77 was below the market price at the time (about $2.50). But the company had the right to do what it did, and their actions could have been anticipated by someone who took the trouble to read the fine print. I also have no doubt that Genzyme tried, as much as possible, to keep that price low so they could get the best deal, but whether they broke the law while doing so I have no idea.

Personally, I wouldn't want to take the other side of any equity deal with Genzyme. Henri Termeer, their CEO, is a wily sort and generally doesn't offer bargains to anyone. This article only confirms that opinion.

Comments (4) + TrackBacks (0) | Category: Business and Markets


COMMENTS

1. anaon..... on September 11, 2007 2:52 PM writes...

Derek, I wonder if you knew about Stanislaw Burzynski and "Antineoplastons for cancer treatment. It would be good if some body can brief things about him.

Permalink to Comment

2. Anonymous BMS Researcher on September 12, 2007 6:03 PM writes...


I know nothing about Antineoplastons, but there is
an article in Wikipedia:
http://en.wikipedia.org/wiki/Antineoplaston

I do not have an opinion concerning the accuracy or otherwise of this article, since I first encountered the term "Antineoplaston" in anaon's posting. So I don't know squat about the subject. Oncology is not among the disease areas of drug discovery in which I have worked.

Derek, do you know anything about this?

Permalink to Comment

3. Anonymous BMS Researcher on September 12, 2007 6:07 PM writes...


Here is what the web site of the American Cancer Society has to say about Antineoplastons:
http://www.cancer.org/docroot/ETO/content/ETO_5_3X_Antineoplaston_Therapy.asp?sitearea=ETO

As with the Wikipedia article, I do not consider myself qualified to have an opinion about Antineoplastons or any other controversial cancer treatment, since I have never worked in Oncology.

Permalink to Comment

4. anaon on September 13, 2007 5:06 PM writes...

Thank you for the links, and the information.

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
XKCD on Protein Folding
The 2014 Chemistry Nobel: Beating the Diffraction Limit
German Pharma, Or What's Left of It
Sunesis Fails with Vosaroxin
A New Way to Estimate a Compound's Chances?
Meinwald Honored
Molecular Biology Turns Into Chemistry
Speaking at Northeastern